A carregar...
Afatinib for the treatment of metastatic non-small cell lung cancer
Targeting the epidermal growth factor receptor (EGFR) in patients with non-small cell lung cancer (NSCLC) harboring sensitizing mutations in the tyrosine kinase (TKI) domain has led to a significant change in the management of this disease. The classic or sensitizing mutations are G719X mutation in...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4340466/ https://ncbi.nlm.nih.gov/pubmed/25733926 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S51808 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|